TRIUMPH-1, the pivotal obesity trial, reported on May 21, 2026 , and TRIUMPH-2 (obesity in type 2 diabetes) and TRIUMPH-3 (obesity with established cardiovascular disease) both reported on July 23, 2026 so the core evidence package for this filing is in hand
Frequently Asked Questions Which is better for weight loss: Semaglutide or Tirzepatide
Patch-based delivery through products like Onmorlo could change the insurance coverage equation by offering a different product category that formulary committees may evaluate independently from injectable GLP-1 medications
Semaglutide is a popular drug used to treat type 2 diabetes and, more recently, for weight loss
Correlation between brain nitric oxide synthase activity and opiate withdrawal
doi: 10.1186/s12885-018-4570-8 92 ZhangYXuFLiangHCaiMWenXLiXet al